The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. ...............These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation.
Showing posts with label KRAS mutation. Show all posts
Showing posts with label KRAS mutation. Show all posts
Friday, March 09, 2012
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking... - Abstract - UK PubMed Central
The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. ...............These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation.
Subscribe to:
Posts
(
Atom
)
